Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Neuronal DAMPs exacerbate neurodegeneration via astrocytic RIPK3 signaling
Nydia P. Chang, … , Rafiq Huda, Brian P. Daniels
Nydia P. Chang, … , Rafiq Huda, Brian P. Daniels
Published May 7, 2024
Citation Information: JCI Insight. 2024;9(11):e177002. https://doi.org/10.1172/jci.insight.177002.
View: Text | PDF
Research Article Immunology Neuroscience

Neuronal DAMPs exacerbate neurodegeneration via astrocytic RIPK3 signaling

  • Text
  • PDF
Abstract

Astrocyte activation is a common feature of neurodegenerative diseases. However, the ways in which dying neurons influence the activity of astrocytes is poorly understood. Receptor interacting protein kinase-3 (RIPK3) signaling has recently been described as a key regulator of neuroinflammation, but whether this kinase mediates astrocytic responsiveness to neuronal death has not yet been studied. Here, we used the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson’s disease to show that activation of astrocytic RIPK3 drives dopaminergic cell death and axon damage. Transcriptomic profiling revealed that astrocytic RIPK3 promoted gene expression associated with neuroinflammation and movement disorders, and this coincided with significant engagement of damage-associated molecular pattern signaling. In mechanistic experiments, we showed that factors released from dying neurons signaled through receptor for advanced glycation endproducts to induce astrocytic RIPK3 signaling, which conferred inflammatory and neurotoxic functional activity. These findings highlight a mechanism of neuron-glia crosstalk in which neuronal death perpetuates further neurodegeneration by engaging inflammatory astrocyte activation via RIPK3.

Authors

Nydia P. Chang, Evan M. DaPrano, Marissa Lindman, Irving Estevez, Tsui-Wen Chou, Wesley R. Evans, Marialaina Nissenbaum, Micheal McCourt, Diego Alzate, Colm Atkins, Alexander W. Kusnecov, Rafiq Huda, Brian P. Daniels

×

Figure 1

Astrocytic RIPK3 signaling promotes neurodegeneration in the MPTP model of Parkinson’s disease.

Options: View larger image (or click on image) Download as PowerPoint
Astrocytic RIPK3 signaling promotes neurodegeneration in the MPTP model ...
(A) Schematic diagram showing treatment paradigm for the subacute MPTP model with selected experimental endpoints used in this study. (B and C) IHC analysis of tyrosine hydroxylase (TH) staining in the substantia nigra pars compacta (SNpc) in indicated genotypes 7 days following either saline or MPTP treatment (scale bar = 200 μm). (D–F) IHC analysis of TH+ axons with colabeling with the damaged axon marker SMI32 in the striatum in indicated genotypes 7 days following either saline or MPTP treatment (scale bar = 20 μm). Insets represent 2× digital zoom of the original 40× images. Arrows represent colocalized puncta for both TH and SMI32 staining. (G) Schematic diagram for the vertical grid test. (H) Behavioral performance in the vertical grid test 7 days after injection with MPTP or saline. n = 4–5 mice/group (B and C), 5–7 mice/group (D–F), 4–11 mice/group (H). Data are represented as mean values with scatterplots depicting individual biological replicate values. All comparisons via 2-way ANOVA with Holm-Šídák multiple-comparison test. *P < 0.05, **P < 0.01, ***P < 0.001. A and G were created with Biorender.com.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts